Septerna
PublicSepterna is now publicly traded
The data on this page reflects Septerna's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 24, 2024
Last Round
Series B
Jul 11, 2023
Total Funding Raised
$581.2M
Company Overview
Septerna is a biotechnology company that develops innovative small molecule medicines aimed at g-protein-coupled receptors, utilizing advanced drug discovery techniques to facilitate the identification of treatments for various diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Septerna Comparables
Compare Septerna with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AstraZeneca | 83% | |
| Incyte Corporation | 81% | |
| Roche Holding | 78% |
For institutional investors. Book with your work email.
Septerna Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Oct 24, 2024 | ||||
| Series B | Jul 11, 2023 | ||||
| Series A | Jan 27, 2022 |
For institutional investors. Book with your work email.
Septerna Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series B |
| RA Capital Management | Series B |
| Vertex Ventures HC | Series B |
| Deep Track Capital | Series B |
| Catalio Capital Management | Series B, Series A |
| TD Cowen | IPO |
| Invus Opportunities | Series B |
For institutional investors. Book with your work email.
Septerna Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.